German drug maker Evotec announced collaboration with U.S. pharmaceutical company Pfizer to advance drug discovery efforts in France.
As per the multi-year master research collaboration and option and license agreement, the companies will initially focus on early discovery research for metabolic and infectious diseases.
Evotec, based in Hamburg, noted that the research would be carried out at its sites in France.
It would be including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics.
Evotec said it would receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programmes. (dpa/NAN
